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Background: Burkholderia pseudomallei is the causative agent of melioidosis, a disease endemic throughout
the tropics.
Methods: A study of reported Acinetobacter spp. bacteraemia was performed at Chiang Rai provincial hospital
from 2014 to 2015. Isolates were collected and tested for conﬁrmation.
Results: A total of 419 putative Acinetobacter spp. isolates from 412 patients were re-identiﬁed and 5/419
(1.2%) were identiﬁed as B. pseudomallei. Four of the ﬁve patients with melioidosis died. An estimated 88/419
(21%) isolates were correctly identiﬁed as Acinetobacter spp.
Conclusions: Misidentiﬁcation of Acinetobacter spp. as B. pseudomallei or other bacteria is not uncommon and
programmes to address these shortfalls are urgently required.
Keywords: Acinetobacter, Burkholderia pseudomallei, laboratory quality assurance, melioidosis, misidentiﬁcation
Introduction
Burkholderia pseudomallei, an environmental Gram-negative
bacterium, is the causative agent of melioidosis.1 There are an
estimated 165 000 human cases with 89 000 deaths annually
worldwide.2 It is thought to be endemic in northern Thailand; how-
ever, only sporadic reports have emerged to date.2 Transmission
occurs through percutaneous inoculation, inhalation or aspiration.1
Risk factors include diabetes mellitus, alcoholism, chronic lung dis-
ease and chronic kidney disease.3
Clinical misdiagnosis of melioidosis regularly occurs due to its
protean manifestations, ranging from mild fever to fatal septic
shock.1,3 Diagnosis is typically made by culture of clinical specimens
and identiﬁcation of B. pseudomallei using conventional microbio-
logical techniques including Gram stain, oxidase test, biochemical
tests and antibiotic susceptibility tests.4,5 Additionally, latex agglu-
tination, identiﬁcation kits (e.g. API20NE), matrix-assisted light
desorption/ionization time-of-ﬂight mass spectrometry (MALDI-
TOF) and molecular tests can provide further conﬁrmation.5
However, laboratory misidentiﬁcation can occur due to lack of
awareness, inadequate quality assurance or limited resources.
Treatment involves an intensive phase with intravenous (IV) cef-
tazidime or meropenem for 10–14 d followed by an eradication
phase of 3–6 months with oral co-trimoxazole or co-amoxiclav.1
Here we report ﬁve culture-conﬁrmed cases whose B. pseudomal-
lei had been misidentiﬁed as Acinetobacter spp.
Materials and methods
A study of reported Acinetobacter spp. bacteraemia was con-
ducted at Chiang Rai provincial hospital, in northern Thailand,
from December 2014 to December 2015. Clinical blood culture
isolates originally identiﬁed as Acinetobacter spp. by the local
hospital laboratory using conventional microbiological techniques
were prospectively collected. These isolates were subcultured and
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Table 1. Clinical summary, radiological ﬁndings and outcomes of ﬁve blood culture–conﬁrmed melioidosis cases in Chiang Rai, Thailand (observations and SOFA scores on admission are
shown)
Patient Age
(y)
Sex Risk factors Temperature
(°C)
HR
(/min)
BP
(mmHg)
RR (/min) SOFA score Presenting
symptoms
Examination
ﬁndings
Radiological
ﬁndings
Working diagnoses Outcome
1 65 M Smoker, chronic
obstructive
pulmonary
disease, lung
abscess
37.5 122 100/60 40 8 Fever, cough,
dyspnoea,
abdominal pain
Reduced breath
sounds on the
left; right upper
quadrant
abdominal pain
CXR: left lung
abscess; US:
hepatic
parenchymal
disease
Chronic lung abscess
with acute
pneumonia, septic
shock, multi-organ
failure
Died within 24 h
of admission
2 62 M Smoker, diabetes
mellitus (new
diagnosis)
35.0 66 69/45 20 9 Fever, abdominal
pain, vomiting
Marked right upper
quadrant
tenderness with
hepatomegaly
CXR: right upper
zone inﬁltration
Septic shock, acute
respiratory distress
syndrome, multi-
organ failure
Died on day 6 of
admission
3 35 M Smoker,
alcoholism,
cirrhosis
37.8 114 125/73 18 2 Fever Hepatomegaly Not done Ongoing melioidosis,
urinary tract
infection
Recovered
4 64 M Diabetes mellitus 36.6 125 130/68 Intubated and
ventilated
14 Fever, cough,
dyspnoea
Right lung
crepitation
CXR: bilateral lung
inﬁltrates
Septic shock, diabetic
ketoacidosis,
pneumonia, multi-
organ failure
Died within 48 h
of admission
5 62 M Chronic kidney
disease
38.5 107 109/73 Intubated and
ventilated
13 Fever, cough,
dyspnoea
Widespread
wheezing and
crepitation
CXR: right lung
inﬁltration
Sepsis, pneumonia,
multi-organ failure
Died on day 6 of
admission
BP: blood pressure; CXR: chest X-ray; HR: heart rate; M: male; RR: respiration rate; SOFA: sequential organ failure assessment; US: ultrasound.
D
ow
nloaded from
 https://academ
ic.oup.com
/trstm
h/advance-article-abstract/doi/10.1093/trstm
h/try108/5116252 by guest on 08 O
ctober 2018
subsequently re-identiﬁed using standard biochemical tests for
conﬁrmation. Additional testing with a B. pseudomallei–speciﬁc
latex agglutination test, VITEK 2 (bioMérieux, Durham, NC, USA)
or MALDI-TOF were performed where necessary. Following labora-
tory conﬁrmation of the identiﬁcation of the isolates, clinical data
were collected retrospectively and recorded on approved case
record forms.
Results and discussion
A total of 419 blood culture isolates reported as Acinetobacter
spp. were obtained from 412 patients, of which 88/419 isolates
(21%) were found to be oxidase positive (Acinetobacter spp.
should be oxidase negative). Five of these (5.7%) were identiﬁed
as B. pseudomallei based on the typical colonial appearance on
Ashdown agar, positive latex agglutination test and VITEK 2 and
MALDI-TOF proﬁles. The remaining oxidase-positive isolates
comprised a variety of environmental bacteria, including
Achromobacter denitriﬁcans (22/88 [25.0%]), Ralstonia mannito-
lilytica (16/88 [18.2%]) and Ochrobactrum anthropi (9/88
[10.2%]). Of the 331/419 oxidase-negative isolates (79%), a
sample of 60 isolates was tested using MALDI-TOF, conﬁrming
the identiﬁcation as Acinetobacter spp. in 16/60 (26.7%) and
Stenotrophomonas maltophilia in 43/60 (71.7%), with 1 isolate
unidentiﬁed. If the sample set was representative, an estimated
88/419 (21.0%) isolates were initially correctly identiﬁed as
Acinetobacter spp.
Clinical summaries of the ﬁve misidentiﬁed melioidosis cases
are presented in Table 1 and details of the blood culture results
for each patient in Table 2. Admission blood cultures were
reported within 22–40 h of collection as Acinetobacter spp.,
while antibiotic susceptibility results were reported 16–24 h
later. All had underlying disease associated with an increased
risk of melioidosis. Four cases had severe disease, were elderly,
developed multi-organ failure and died (patients 1, 2, 4 and 5).
The initial empirical treatment in these patients included IV cef-
triaxone or IV piperacillin/tazobactam with additional antibiotics
in some cases (e.g. amikacin, roxithromycin, azithromycin, doxy-
cycline and vancomycin). Only two of the four severe cases
received melioidosis-appropriate antibiotics—IV meropenem in
both cases—with delays of 1 and 4 d from admission (patients
2 and 5, respectively). The other two severe cases died within 48
h of admission (patients 1 and 4). The patient who survived was
younger, had mild disease, had previously been diagnosed with
genitourinary tract melioidosis and was already on appropriate
treatment (IV ceftazidime), which was continued despite the
misleading admission blood culture result (patient 4).
In this report we conﬁrm the presence of melioidosis in nor-
thern Thailand and demonstrate that laboratory misidentiﬁca-
tion of Acinetobacter spp. as B. pseudomallei or other bacteria
remains commonplace. The predicted mortality from melioidosis
Table 2. Details of the blood culture results reported for the ﬁve misidentiﬁed melioidosis cases from Chiang Rai, Thailand
Patient Collection time (day
0=admission)
Report time (hours
after collection)
Results Antibiotic susceptibility (S = Sensitive, I = Intermediate
sensitivity, R = Resistant)
1 Day 0 37 h Acinetobacter lwofﬁi S—ceftazidime, imipenem, cefoperazone/sulbactam
R—amikacin, gentamicin, co-trimoxazole
2 Day 0 28 h Mixed growth: A. lwofﬁi,
Staphylococcus epidermidis
S—ceftazidime, imipenem, piperacillin-tazobactam,
cefoperazone/sulbactam, ciproﬂoxacin, ertapenem,
meropenem, cefotaxime, co-trimoxazole
R—amikacin, gentamicin
NB—susceptibility results for Acinetobacter lwofﬁi only
Day 2 99 h Burkholderia pseudomallei S—ceftazidime, imipenem, cefoperazone/sulbactam
R—amikacin, gentamicin, co-trimoxazole
3 Day 0 40 h Acinetobacter baumannii S—ceftazidime, doripenem, imipenem, piperacillin-
tazobactam, cefoperazone/sulbactam, ertapenem,
meropenem, cefotaxime
R—amikacin, gentamicin, co-trimoxazole
4 Day 0 22 h A. baumannii S—ceftazidime, doripenem, imipenem, piperacillin-
tazobactam, cefoperazone/sulbactam, ertapenem,
meropenem, cefotaxime
R—amikacin, gentamicin, co-trimoxazole
5 Day 0 25 h A. lwofﬁi S—ceftazidime, doripenem, imipenem, piperacillin-
tazobactam, cefoperazone/sulbactam, ertapenem,
meropenem
I—cefotaxime
R—amikacin, gentamicin, co-trimoxazole
NB: antibiotic susceptibility results were generally reported 16–24 h after the blood culture ﬂagged positive.
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in Thailand is 37.5%, while 4/5 (80%) patients in this study
died.2 This conﬁrms the high mortality associated with melioid-
osis, especially when compounded by misdiagnosis and delays
in initiating effective treatment. However, earlier initiation of
appropriate antibiotics alone, without timely and adequate
intensive care support, may not improve the outcome in severe
disease.3 Empirical ceftriaxone and piperacillin/tazobactam
were used: ceftriaxone has moderate in vitro activity against B.
pseudomallei, while susceptibility to piperacillin/tazobactam has
also been shown.6,7 Despite these ﬁndings, ceftriaxone is less
effective than ceftazidime and clinical experience with piperacil-
lin/tazobactam is limited.8 Correct identiﬁcation on admission
blood culture might have improved the outcome in one patient
where appropriate treatment was delayed for 4 d. Even in
endemic areas, microbiology laboratories can struggle to iden-
tify B. pseudomallei. Training and introduction of a simple
laboratory algorithm have been shown to be effective in diag-
nosing melioidosis in Vietnam.4 During the study period, nine
other patients had melioidosis diagnosed from positive blood
cultures, demonstrating that local laboratory staff are capable
of identifying B. pseudomallei, albeit inconsistently. In addition,
this study shows that data from routine laboratory-based sur-
veillance systems, even in countries like Thailand with relatively
well-developed health care facilities, should be treated with
caution.
Conclusions
Making the correct diagnosis is vital to patient outcome and
fundamental to any effective surveillance and antimicrobial
stewardship programmes. The diagnosis and management of
melioidosis remain suboptimal in many endemic regions. The
misidentiﬁcation of B. pseudomallei and other bacteria demon-
strated in this report highlights the need to prioritize and
strengthen laboratory capacity and quality. Following discus-
sions with local stakeholders, plans are under way to provide
additional training, improve quality assurance and introduce
consistent use of new diagnostics (e.g., latex agglutination test,
API20NE and VITEK) within the microbiology laboratory. Efforts
to increase the clinical awareness of melioidosis, including the
importance of effective and timely treatment in at-risk patients,
are also required.
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